Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company, is preparing for a clinical trial event by the end of this year.
The company's lead drug candidate is Onvansertib, a PLK1 inhibitor, which in combination with standard-of-care (SoC) therapeutics is targeting indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.